Proactive Investors - Run By Investors For Investors

Ceapro to begin clinical trials for beta glucan to treat high cholesterol

Ceapro Inc (CVE: CZO) CEO Gilles Gagnon tells Proactive Investors the company will soon begin enrollment in clinical trials of its cholesterol-fighting beta glucan.

Meanwhile, the Canadian-based biotech company's recent positive findings indicate its PGX Technology can be used as a delivery system for use on the skin or as a fast-acting oral drug.

View full CZO profile View Profile

Ceapro Inc. Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use